NSE · SAKAR
Sakar Healthcare Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹73 Cr with net profit ₹10 Cr — a 14.09% net margin, versus 15.5% the period before.
Shareholding
As of 2026-06-30
- Promoter52.52%
- Public23.98%
- FII12.14%
- DII11.37%
14,734 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 3.71× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — LT-ASM · ASM 2. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #46 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,516 Cr | 35.34 | 5.34 | 13.74% | 20.29% |
| Zydus Lifesciences Ltd. | ₹1,11,501 Cr | 22.84 | 4.11 | 18.59% | 16.09% |
| Cipla Ltd. | ₹1,10,943 Cr | 31 | 3.22 | 11.27% | 12.06% |
| Laurus Labs Limited | ₹1,05,091 Cr | 96.1 | 19.83 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹95,996 Cr | 25.39 | 2.53 | 9.25% | 10.7% |
| Dr Reddys Laboratories Ltd. | ₹95,404 Cr | 29.61 | 2.51 | 11.07% | 9.73% |
| Lupin Limited | ₹95,011 Cr | 15.95 | 4.23 | 23.76% | 18.72% |
| Mankind Pharma Limited | ₹92,456 Cr | 43.34 | 5.67 | 11.74% | 13.86% |
| Glenmark Pharmaceuticals Ltd. | ₹68,157 Cr | 21.84 | 6.48 | 28.08% | 10.22% |
| Biocon Ltd. | ₹63,558 Cr | 87.05 | 1.84 | 1.14% | 2.89% |
| Sakar Healthcare Limited(this company) | ₹2,486 Cr | 68.88 | 7.66 | 9.4% | 13.27% |
AI analysis
AI-generated · google/gemini-2.5-flashSakar Healthcare Limited (SAKAR) has a market capitalization of Rs 2000 Cr. The company reported a revenue of Rs 178.9 Cr with a profit margin of 12.11%. The promoter holding stands at 52.86% as of March 31, 2026.
Positives
- +Revenue grew 15.8% to Rs 178.9 Cr.
- +The company's debt-to-equity ratio is low at 0.3.
- +Promoter holding is above 50% at 52.86% as of March 31, 2026.
- +There are no reported promoter share pledges.
Negatives
- −The Return on Equity (ROE) is 9.4%, which is below 10%.
- −Quarterly net profit declined from Rs 5.76 Cr in Mar 2025 to Rs 4.67 Cr in Jun 2025 and further to Rs 4.54 Cr in Sep 2025.
- −The dividend yield is 0%, indicating no dividend payout.
- −The PE ratio is high at 65.61.
Financial Performance
Sakar Healthcare Limited recorded a revenue of Rs 178.9 Cr, demonstrating a revenue growth of 15.8%. The net profit margin for the latest reported period stands at 12.11%. The company's EPS is Rs 13.7. Quarterly revenue has shown an increase, from Rs 43.42 Cr in Dec 2024 to Rs 71.1 Cr in Mar 2026, with net profit rising from Rs 4.53 Cr to Rs 11.02 Cr in the same period.
Profitability & Returns
The company's profit margin is 12.11%. Return on equity (ROE) is 9.4%, and return on capital employed (ROCE) is 12.54%. The company's PE ratio is 65.61, and its book value per share is Rs 145.82.
Balance Sheet
Sakar Healthcare Limited has a debt-to-equity ratio of 0.3. The company also reports a book value of Rs 145.82 per share.
Ownership & Pledges
As of March 31, 2026, the promoter holding in Sakar Healthcare Limited is 52.86%. Public shareholders account for 22.87%. There are no reported promoter share pledges.
Regulatory & Surveillance
The company is not currently under any surveillance measure. No pledges by promoters have been reported as of the latest disclosure (March 31, 2026).
Data as of — price: 2026-09-10 · financials: Jun 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.